Alnylam Pharmaceuticals | ALNY - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amgen USD 1.72B 134M 2026-06
Arrowhead Research USD 46.63M 4.88M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Incyte USD 351.73M 23.64M 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Moderna USD 216M 43M 2026-06
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.14B 296M 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.49B 252M 2026-03
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Takeda JPY 286.51B 5.48B 2026-06
Tectonic Therapeutic USD 6.43M 2.99M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06
Xencor USD 77.54M 4.59M 2026-06